

# Danilo Menichelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2139746/publications.pdf>

Version: 2024-02-01

50  
papers

1,644  
citations

361413

20  
h-index

315739

38  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	3.4	219
2	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 441-451.	2.4	28
3	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry. <i>Platelets</i> , 2022, , 1-6.	2.3	0
4	Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1260.	4.1	10
5	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk—A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 785.	2.5	4
6	Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department. <i>Internal and Emergency Medicine</i> , 2022, 17, 1777-1784.	2.0	7
7	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	2.0	21
8	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2021, 46, 100410.	2.4	7
9	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13771.	1.7	14
10	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 141, 1-6.	1.6	5
11	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021, 96, 658-665.	3.0	22
12	Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13397.	3.4	21
13	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605,771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f11-f19.	3.0	40
14	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	1.7	1
15	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021, 127, 2122-2129.	4.1	45
16	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	2.2	21
17	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2063-2068.	2.0	5
18	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021, 26, 1425.	3.8	12

#	ARTICLE	IF	CITATIONS
19	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. <i>Italian Journal of Emergency Medicine</i> , 2021, 10, .	0.1	3
20	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 28-36.	3.1	25
21	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715878.	2.4	39
22	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 698008.	3.5	20
23	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	1.7	35
24	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779503.	2.4	8
25	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , 2020, 15, 135-143.	2.0	21
26	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008477.	4.8	3
27	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13378.	3.4	141
28	Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. <i>Nutrients</i> , 2020, 12, 3379.	4.1	30
29	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2455-2463.	2.4	24
30	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 866-875.	3.4	52
31	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	3.5	81
32	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. <i>International Journal of Cancer</i> , 2020, 147, 3424-3430.	5.1	8
33	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , 2020, 4, 1034-1040.	4.3	22
34	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	2.5	14
35	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , 2019, 289, 195-200.	0.8	12
36	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 561-576.	2.6	20

#	ARTICLE	IF	CITATIONS
37	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 17.	2.4	8
38	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	3.0	89
39	Silybin and metabolic disorders. <i>Internal and Emergency Medicine</i> , 2019, 14, 1-3.	2.0	7
40	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 6, 1.	0.4	1
41	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018, 54, 34-39.	2.2	18
42	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , 2018, 17, 830-836.	1.0	5
43	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , 2018, 264, 58-63.	1.7	69
44	Hazelnut and cocoa spread improves flow-mediated dilatation in smokers. <i>Internal and Emergency Medicine</i> , 2018, 13, 1211-1217.	2.0	7
45	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , 2018, 76, 713-722.	0.6	150
46	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	105
47	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1455-1462.	2.8	57
48	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	7.1	22
49	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 751-755.	5.4	15
50	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	51